Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination With AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients With Advanced Cancer

NCT04121676 is registered in ClinicalTrials.gov with Agenus Inc. as lead sponsor.

NCT NCT04121676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04121676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination With AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients With Advanced Cancer
Lead sponsor
Agenus Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 26, 2019
Completion date
November 30, 2024
Enrollment
91 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer